ZURICH (Reuters) – Lonza has signed a partnership agreement with Anthos Therapeutics, the Swiss company said on Thursday, to develop and manufacture an antibody treatment for blood clots.
Anthos, a biotech created by Blackstone Life Sciences and Novartis, will get access to Lonza’s drug substance, drug product and labeling/packaging services to speed the launch of Abelacimab, a treatment for patients at risk of thrombosis.
(Reporting by John Revill; editing by Thomas Seythal)
Collin Morikawa part of 4-way tie for the lead at Hilton Head. Scottie Scheffler lurks 3 shots back
Nuggets forward Michael Porter Jr. heads into playoffs against Lakers after trying week for family
Mario Andretti offended by F1 rejection. ‘If they want want blood, well, I’m ready,’ says 1978 champ
Coyotes’ move to Salt Lake City elicits opposing responses in 2 cities
Buffalo Bills owner Terry Pegula explores selling non-controlling, minority stake in franchise
Seeking ‘the right side of history,’ Speaker Mike Johnson risks his job to deliver aid to Ukraine
Idaho group says it is exploring a ballot initiative for abortion rights and reproductive care
Man who won primary election while charged with murder convicted on lesser charge
Thai plastics firm will pay $20 million to settle with U.S. over Iran sanctions violations
Mayor Adams restores $500 million for education, leaves open-ended questions about free child care in NYC
BNSF Railway says it didn’t know about asbestos that’s killed hundreds in Montana town
Soldiers who lost limbs in Gaza fighting are finding healing on Israel’s amputee soccer team
Nevada Supreme Court rulings hand setbacks to gun-right defenders and anti-abortion activists
As syphilis cases among US newborns soar, doctors group advises more screening during pregnancy
